Big Sky Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2012


Here are the related meetings in 2018:
The Resolution of Inflammation in Health and Disease (C6)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics (D1)


Organizer(s) Paul W. Noble, Shelia M. Violette and Scott L. Friedman
March 30—April 4, 2012
Big Sky Resort • Big Sky, Montana USA
Abstract Deadline: Nov 30, 2011
Late Abstract Deadline: Jan 5, 2012
Scholarship Deadline: Nov 30, 2011
Early Registration Deadline: Jan 30, 2012

Sponsored by Bayer USA Foundation, Celgene Corporation, GlaxoSmithKline UK, Hoffmann-La Roche, Inc. and Regulus Therapeutics Inc.

Summary of Meeting:
Fibrosis is a pathological process in which diseased tissue is replaced with excess extracellular matrix ultimately leading to organ scarring and failure, a final common pathway in many forms of chronic disease affecting multiple tissues. Currently, there are minimal and inadequate treatment options for fibrotic disease. There is an urgent need to understand the cellular, molecular and genetic basis of fibrosis in humans and develop animal models that replicate and illuminate this pathological process. There is also a need to identify prognostic markers of disease susceptibility, biomarkers of disease progression and improved technologies to monitor the effectiveness of new therapies. The goal of the Keystone Symposia meeting on Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics is to bring together researchers and clinicians in academia and industry to provide an integrated perspective of basic disease mechanisms, and to address the more pragmatic challenges associated with executing clinical trials and refining approaches to accelerate the clinical development of anti-fibrotic drugs.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


FRIDAY, MARCH 30

15:00—19:30
Registration

Lower Atrium
18:15—19:15
Refreshments

Lower Atrium
19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Jefferson/Madison
* Paul W. Noble, Cedars-Sinai Medical Center, USA

Eric N. Olson, University of Texas Southwestern Medical Center, USA
MicroRNAs in Tissue Remodeling and Disease


SATURDAY, MARCH 31

07:00—08:00
Breakfast

Upper Atrium/Lower Atrium
08:00—11:15
Epithelial Injury, Tissue Remodeling and Repair
Meeting has ended...abstracts no longer viewable online.

Jefferson/Madison
Rachel C. Chambers, University College London, UK
Coagulation Cascade, Tissue Injury and Repair in the Lung

Victor J. Thannickal, University of Alabama, Birmingham, USA
Targeting the Myofibroblast in Fibrotic Lung Disease

Harold A. Chapman, University of California, San Francisco, USA
Epithelial Responses to Lung Injury: Role of the Extracellular Matrix

* Dean Sheppard, University of California, San Francisco, USA
Roles for alphav Integrins on Epithelial Cells and Myofibroblasts in Regulating Tissue Fibrosis

Lynn M. Schnapp, Medical University of South Carolina, USA
Short Talk: Role of Urokinase Plasminogen Activator Receptor Associated Protein (uPARAP) in Lung Injury and Repair

Vladimir V. Kalinichenko, Cincinnati Children's Hospital Medical Center, USA
Short Talk: Foxm1 Transcription Factor Increases Epithelial-to-Mesenchymal Transition and is Required for Radiation-Induced Pulmonary Fibrosis

09:20—09:40
Coffee Break

Lower Atrium
11:15—13:00
Poster Setup

Gallatin
11:15
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Gallatin
16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Unfolded Protein Response and Endoplasmic Reticulum-Stress-Induced Injury
Meeting has ended...abstracts no longer viewable online.

Jefferson/Madison
* Gisli Jenkins, University of Nottingham, UK

David Ron, University of Cambridge, UK
Unfolded Protein Stress in the Endoplasmic Reticulum and the Extracellular Matrix

Timothy S. Blackwell, Vanderbilt University School of Medicine, USA
Dysfunctional Alveolar Epithelial Cells as a Result of Mutant Surfactant Protein C Expression: A Potential Link to Pathogenesis of IPF

Gökhan S. Hotamisligil, Harvard University, USA
ER Stress, Chronic Inflammation, and Metabolic Disease

Natalie J. Torok, University of California, Davis, USA
Short Talk: TIMP3/TACE Controls Inflammatory and Fibrogenic Activity in Non Alcoholic Steatohepatitis via NADPH Oxidase-Derived Reactive Oxidative Species

19:00—20:00
Social Hour with Lite Bites

Upper Atrium/Lower Atrium
19:30—22:00
Poster Session 1

Gallatin

SUNDAY, APRIL 1

07:00—08:00
Breakfast

Upper Atrium/Lower Atrium
08:00—11:15
Progenitor Cells and Cellular Plasticity in Fibrosis
Meeting has ended...abstracts no longer viewable online.

Jefferson/Madison
Raghu Kalluri, University of Texas MD Anderson Cancer Center, USA
Organ Fibrosis: Mechanism and Molecular Connection to Cancer

Jeremy S. Duffield, Vertex Pharmaceuticals, USA
Cell Fate Mapping and Pericytes in Kidney Injury and Fibrosis

* Anna Mae Diehl, Duke University Medical Center, USA
Hedgehog, Progenitors and Epithelial Progenitors

David A. Brenner, University of California, San Diego, USA
Fibrosis from EMT and Non-Resident Mesenchymal Cells - Fact or Fiction?

Jelena Mann, Newcastle University, UK
Short Talk: Protective Adaptation to Liver Fibrosis in a Single Generation by Heritable Epigenetic Modifications

Ivan Bertoncello, University of Melbourne, Australia
Short Talk: Regulation of Endogenous Lung Epithelial Stem/Progenitor Cells by Lung Mesenchymal Cells and Cytokines

09:20—09:40
Coffee Break

Lower Atrium
11:15—13:00
Poster Setup

Gallatin
11:15
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Gallatin
14:00—16:30
Workshop 1: Development of Novel Therapeutics in Fibrotic Disease

Jefferson/Madison
* Shelia M. Violette, Admirx Inc., USA

Steven R. Ledbetter, Genzyme Corporation, USA
Neutralizing TGF-beta: A Promising Approach for the Treatment of Chronic Diseases

Eva van Rooij, Hubrecht Institute, Netherlands
Novel Therapeutics in Cardiovascular Disease and Tissue Remodeling

Mark L. Lupher, Jr., Muregen, LLC, USA
PRM-151, Recombinant Human Pentraxin-2: Preclinical and Clinical Progress

James S. Swaney, Inception Sciences, USA
LPA1 Receptor Antagonism in Fibrotic Disease

Victoria Smith, Gilead Sciences, USA
Targeting Loxl2 in Fibrotic Disease

Anne Minnich, Sanofi Phamaceuticals, USA
SAR156597: An Innovative Bi-Specific IL-4/IL-13 Antibody as a Potential Treatment for Idiopathic Pulmonary Fibrosis

16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Tissue Remodeling in the Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online.

Jefferson/Madison
* Sandra S. McAllister, Brigham & Women's Hospital/Harvard Medical School, USA
The Systemic Environment as a Powerful Determinant of Stromal Desmoplasia and Tumor Malignancy

Jeffrey W. Pollard, Queen's Medical Research Institute, UK
Role of Macrophages and Tissue Remodeling in the Tumor Microenvironment

Robert F. Schwabe, Columbia University, USA
Promotion of Hepatocarcinogenesis by Activated Hepatic Stellate Cells

Janusz Franco-Barraza, Fox Chase Cancer Center, USA
Short Talk: alphavbeta5/alpha5beta1-Integrin Crosstalk is Necessary to Maintain a Tumor-ECM Induced Myofibroblastic Phenotype

19:00—20:00
Social Hour with Lite Bites

Upper Atrium/Lower Atrium
19:30—22:00
Poster Session 2

Gallatin

MONDAY, APRIL 2

07:00—08:00
Breakfast

Upper Atrium/Lower Atrium
08:00—11:15
Innate and Adaptive Mechanisms of Fibrosis
Meeting has ended...abstracts no longer viewable online.

Jefferson/Madison
* Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA

Thomas A. Wynn, Pfizer, USA
Regulation of Fibrosis by IL-13, IL-17, and Macrophages

Paul W. Noble, Cedars-Sinai Medical Center, USA
Innate Immune Regulation of Lung Fibrosis

Andrew P. Fontenot, University of Colorado Denver, USA
Immune Mechanisms of Lung Fibrosis in Granulomatous Inflammation

Tamiko R. Katsumoto, University of California, San Francisco, USA
Short Talk: The Receptor-Type Protein Tyrosine Phosphatase CD148 Positively Regulates Pro-Fibrotic Signaling Pathways in Bleomycin-Induced Lung Fibrosis

William C. Parks, University of Washington, USA
MMPs Shape Fibrosis via Controlling Macrophage Activation

Christian Stockmann, PARCC – Paris Cardiovascular Research Center, France
Short Talk: Aberrant Remodeling of the Lymphatic Vasculature during Pulmonary Fibrosis – The Lymphatic Drainage Capacity as a Determinating Factor of Fibroproliferative Changes in the Lung

09:20—09:40
Coffee Break

Lower Atrium
11:15—13:00
Poster Setup

Gallatin
11:15
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Gallatin
14:00—16:30
Workshop 2: Modeling Injury and Fibrosis

Jefferson/Madison
* Martin R. J. Kolb, McMaster University, Canada

Pär Gerwins, Uppsala University, Sweden
An in vivo Neovascularization Assay for Screening Regulators of Angiogenesis and Assessing their Effects on Pre-Existing Vessels

Emily Hamburg, Case Western Reserve University, USA
Stabilized beta-Catenin Activity in Dermal Fibroblasts Leads to Skin Fibrosis

Lukasz Stawski, Boston University, USA
Angiotensin II Induces Skin Fibrosis: A Novel Mouse Model of Dermal Fibrosis

Tomoko Hayashida, Northwestern University, USA
Distinct and Sequential Roles for PI3Ks and TGF-beta Mediating Glomerular Sclerosis in Mouse Adriamycin Nephropathy

Matthew Frieman, University of Maryland, USA
Contribution of Alternatively Activated Macrophages to a Pro-Fibrotic Response during SARS Coronavirus Infection

Reinout Stoop, TNO, Netherlands
Combination of Deuterated Water Labeling and Transcriptomics Analysis Identifies Processes Contributing to Collagen Deposition during Pulmonary Fibrosis

16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Fibroblasts and Myofibroblasts
Meeting has ended...abstracts no longer viewable online.

Jefferson/Madison
Sem H. Phan, University of Michigan Medical School, USA
Regulation of Myofibroblast Differentiation

* Rebecca G. Wells, University of Pennsylvania, USA
Myofibroblasts in Liver Fibrosis

John Varga, Feinberg School of Medicine, USA
Impaired PPAR-gamma Signaling in Scleroderma: Therapeutic Target

Claire Dugast-Darzacq, Institut de Biologie de l' École Normale Supérieure (IBENS), France
Short Talk: Identification of Key Transcription Factors in the Regulation of Fibroblast to Myofibroblast Differentiation in an ex vivo Model of Chronic Wound

19:00—20:00
Social Hour with Lite Bites

Upper Atrium/Lower Atrium
19:30—22:00
Poster Session 3

Gallatin

TUESDAY, APRIL 3

07:00—08:00
Breakfast

Upper Atrium/Lower Atrium
08:00—11:15
Biomarkers in Fibrotic Disease: Facilitating Clinical Development
Meeting has ended...abstracts no longer viewable online.

Jefferson/Madison
* Michael Gilman, Padlock Therapeutics, USA

Naftali Kaminski, Yale University School of Medicine, USA
RNA, microRNA and Protein Biomarkers in Interstitial Lung Disease

Shelia M. Violette, Admirx Inc., USA
Developing a Biomarker Strategy to Support the Clinical Development of STX-100, an alphavbeta6 Antibody, in Fibrotic Disease

Robert Lafyatis, University of Pittsburgh Medical Center, USA
Biomarkers as Predictors of Disease in Scleroderma

Gabe Kwong, Georgia Institute of Technology, USA
Nanoparticle-Based Urinary Biomarkers in Liver Disease

Kenn Holmbeck, NIDCR, National Institutes of Health, USA
Short Talk: Connective Tissue Homeostasis is Dependent on Membrane-Type Matrix Metalloproteinase (MT-MMP) Activity for Resolution of Fibrosis

Peter Caravan, Harvard Medical School, Massachusetts General Hospital, USA
Short Talk: Collagen-Targeted Molecular MR Imaging of Liver Fibrosis

09:20—09:40
Coffee Break

Lower Atrium
11:15
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
What's New in the Field: Clinical Developments in Fibrosis
Meeting has ended...abstracts no longer viewable online.

Jefferson/Madison
* Richard P. Marshall, GlaxoSmithKline, UK

Williamson Z. Bradford, Intermune, Inc., USA
IPF Drug Development: Trials, Tribulations, and New Opportunities

Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Prospects for Antifibrotics in Liver Disease

Timothy W. Schacker, University of Minnesota, USA
Short Talk: Antifibrotic Therapy in SIV Infection Preserves CD4 T Cell Populations and Improves Immune Reconstitution With Antiretroviral Therapy

Christopher L. Leptak, Food and Drug Administration, USA
Biomarker Utility in Drug Development and Clinical Trials: An FDA Regulatory Perspective

19:00—20:00
Social Hour with Lite Bites

Upper Atrium/Lower Atrium
20:00—23:00
Entertainment

Madison/Gallatin

WEDNESDAY, APRIL 4

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Bayer USA Foundation Celgene Corporation
GlaxoSmithKline UK Hoffmann-La Roche, Inc.
Regulus Therapeutics Inc.
 

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13HL112456-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

InterMune, Inc. Promedior, Inc.
Stromedix, Inc.
Celera

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Bristol-Myers Squibb Company


Stromedix, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676